TROY HENDERSON: Open Payments
NPI 1609324003 · FULTONDALE, AL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,929 in 153 payments from 29 companies in 2025. Trend: 2023 $3,685 · 2024 $4,505 · 2025 $2,929
Food & beverage: $2,929
| Company | Payments | Amount |
|---|---|---|
| GlaxoSmithKline, LLC. | 14 | $368 |
| ABBVIE INC. | 27 | $352 |
| AstraZeneca Pharmaceuticals LP | 16 | $341 |
| Novo Nordisk Inc | 14 | $238 |
| Amgen Inc. | 9 | $174 |
| Bayer Healthcare Pharmaceuticals Inc. | 9 | $162 |
| Lilly USA, LLC | 8 | $145 |
| PFIZER INC. | 7 | $140 |
| Axsome Therapeutics, Inc. | 5 | $117 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $111 |
Products named: TRELEGY ELLIPTA, Kerendia, VRAYLAR, UBRELVY, JARDIANCE, FARXIGA, Ozempic, Auvelity.
Industry payments across AL — which companies pay providers there.
